IntegrateRNA Offers Epitranscriptome Services for Transcriptome-wide RNA Modification Analysis and Accelerate RNA Medicines Development

IntegrateRNA announced the release of epitranscriptome services with its advanced NGS platform to accelerate the creation and development of truly and effective RNA medicines.

New York, USA – January 19, 2021 – IntegrateRNA, a branch of Creative Biogene biotechnology company, is a global leading provider of RNA discovery, expression analysis, functional research and mechanism analysis. IntegrateRNA is dedicated to developing unique technologies that provide satisfactory services to scientists around the world, enabling researchers to better understand human diseases. Recently it announced the release of epitranscriptome services with its advanced NGS platform to accelerate the creation and development of truly and effective RNA medicines.

RNA modification occurs in different locations of natural RNA and affects several biological processes. For example, the modification of eukaryotic mRNA can affect the metabolism, function and degradation of mRNA. The modification of non-coding RNA is important to maintain the proper function of ncRNA in translation and splicing. Several transcriptome sequencing technologies have been proposed, including MeRIP-seq, RNA-BS-seq, acRIP-seq, m6Am-Exo-seq, miCLIP, and direct RNA sequencing to preserve RNA modification information and convert it into quantitative and measurable signal. These new tools have helped researchers identify the location of RNA modifications and revealed the unique distribution of these modifications throughout the transcriptome.

Based on years of experience and professional bioinformatics capabilities, IntegrateRNA provides sensitive, powerful and transcriptome-wide RNA modification detection services to accelerate the speed of epigenetics research, including but not limited to MeRIP-seq Service, RNA Bisulfite Sequencing Service, acRIP-seq Service.

IntegrateRNA can quickly, efficiently and accurately identify m6A modification sites in mRNA transcripts and other RNAs through methylated RNA immunoprecipitation sequencing (MeRIP-seq). Combining co-immunoprecipitation and high-throughput sequencing can systematically study m6A peaks and m6A motifs in the transcriptome, and analyze the most prominent transcriptome m6A modifications by methylated RNA immunoprecipitation sequencing (MeRIP-seq).

IntegrateRNA uses advanced sequencing technology to provide basic resolution RNA methylation (m5C) analysis services across the entire transcriptome, utilizing classic bisulfite processing and next-generation sequencing platforms to detect m5C across the entire transcriptome Methylation modification. IntegrateRNA is committed to providing high-resolution, efficient and economical methods for m5C detection and localization of various RNA molecules (such as mRNA, tRNA, rRNA). Treating RNA samples with bisulfite, and then performing PCR amplification, cloning and sequencing of single amplicons, promotes the study of RNA methylation at single cytosine single base resolution. The available data analysis items include: m5C modification level analysis; m5C modify site statistics and notes; identification and statistics of differences in methylated cytosine; tailored data analysis.

In addition, recent studies have shown that ac4C is related to the occurrence, development and prognosis of a variety of human diseases. ac4C helps to read codons correctly during translation, and improves translation efficiency and mRNA stability. IntegrateRNA uses ac4C-specific RNA immunoprecipitation and high-throughput sequencing (acRIP-seq) methods to provide efficient, unbiased ac4C detection and location services across the transcriptome. Based on the advanced NGS platform and experienced bioinformatics professionals, IntegrateRNA is committed to providing one-stop solutions from samples to data.

“IntegrateRNA is committed to providing customers with high-quality data for epitranscriptome research. Through consulting, flexible, integrated and interdisciplinary methods, we provide suggestions and services to advance your project schedule.” said Marcia Brady, the marketing director of Creative Biogene, she also claimed, “For specific needs, our in-house professionals can also offer customized solutions according to research requirements.”

About IntegrateRNA

IntegrateRNA, as the division of Creative Biogene that holds a leading position in providing complete solutions for RNA research, has years of experience in next-generation sequencing and develops microarray platforms that enable researchers to explore the world of RNA on an unprecedented scale, and mapping all RNAs involved in cell life programs, human diseases, and drug discovery.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-386-8241
Country: United States